Each treatment involves subcutaneous injections, which can be easily done at home after receiving training and guidance from our team
This is the acclimation phase
Abbreviations GLP-1: Glucagon Like Peptide-1 CV: Cardio Vascular DPP-4: DiPeptidylPeptidase-4 USFDA: United States Food & Drug Administration Aib: 2-Aminoisobutyric acid SNAC: Sodium-N-[8-(2-hydroxybenzoyl)amino]caprylate SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes FPG: Fasting Plasma Glucose HOMA-B: Homeostasis model assessment of -cell function ER: Extended release DXA: Dual energy X-ray Absorptiometry OAD: Oral Antidiabetic Drugs SGLT-2: Sodium GLucose co-Transporter-2 SMBG: Self-Monitoring of Blood Glucose PIONEER: Peptide Innovation for Early Diabetes Treatment EMA: European Medicines Agency References Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE

The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial
The study population included 7,249 adult patients with registry-identified T2D who initiated prescribed oral semaglutide (a GLP-1 receptor agonist) treatment between April 1, 2021, and December 31, 2023